Diasorin S.p.a. · MIL:DIA
Diasorin — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
16 slides from Diasorin's conference presentation, Jan 15, 2025
Slide 1: 43rd Annual J.P. Morgan Healthcare Conference
43rd Annual J.P. Morgan Healthcare Conference Carlo Rosa, CEO San Francisco, CA – January 15th, 2025
Slide 2: Disclaimer
Disclaimer In General. This disclaimer applies to this presentation and any oral comments of any person presenting it. This document, taken together with any such oral comments, is referred to herein as the “Presentation”. This Presentation has been prepared by Diasorin S.p.A. (“Diasorin” or the “Co
Slide 3: Forward-looking statements
Forward-looking statements This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: Leader in the Diagnostic market, with a Life Science B2B unique offering
• Leader in the Diagnostic market, with a Life Science B2B unique offering • Listed on the Italian Stock Exchange since 2007 and included in the FTSE MIB Index In Vitro Diagnostic (~ €60 billions market size) Life Science Immunodiagnostics Molecular Diagnostics Licensed Technologies (~ €14 billions
Slide 5: Worldwide
worldwide NORTH AMERICA ~50% of Group Revenues NORTH AMERICA EUROPE USA Italy EUROPE Austin Madison Saluggia Chicago Stillwater Bresso Cypress ~35% of Group Revenues Germany Dietzenbach ASIA China Canada UK Toronto Baoshan REST OF WORLD Dartford ~15% of Group Revenues LEGEND Direct presence Coutries
Slide 6: Immunodiagnostic Strategic Development
Immunodiagnostic Strategic Development 1.0 2.0 3.0 2001 2010 2023 PHASE 1 PHASE 2 PHASE 3 RIA/EIA EIA/CLIA FOCUS on new paradigm Diasorin stand alone Menu expansion also via Development of new biomarkers and 80 tests ca. partnerships & acquisitions markets 120 tests ca. Value Based Care products • C
Slide 7: Immunodiagnostic Specialist
Immunodiagnostic Specialist We have the broadest immunoassay menu available specialties market share* on the market Infectious disease Bone & mineral 84 63 40% 22% 46 Calprotectin Renal metabolism 32 37% 31% Differentiating & High-Volume Specialties High-routine tests immunoassay tests Tests of the
Slide 8: New programs supporting the specialist positioning
New programs supporting the specialist positioning LIAISON® MeMed BV® QuantiFERON® TB • Algorithm-based diagnostic test differentiating between • Golden standard solution for Latent Tubercolosis (TB) testing Bacterial vs Viral infections • WHO estimates 25% of population is affected by TB • Clinical
Slide 9: Molecular Diagnostics: Multiplexing Capabilities
Molecular Diagnostics >10 plex Gastrointestinal LIAISON ~$ 380M MAGPIX® / PLEX® NxTag MULTIPLEXING CAPABILITIES Blood Culture ~$ 120M 10 plex CNS Respiratory ~$ 50M ~$ 2.0B Blood Borne ~$ 880M STI 1-6 plex HPV, CT/NG ~$ 160M HAI ~$ 1.8B ~$ 630M LIAISON® NES LIAISON® MDX / LIAISON® MDX Plus 1 2-4 8 -
Slide 10: LIAISON PLEX: Flex Testing Technology
LIAISON PLEX®: Flex Testing Technology LIAISON PLEX®: FLEXIBLE APPROACH Select 7 most prevalent targets Select additional 6 targets Select additional 6 targets 10% negative 0.5% negative (instant reflex) (instant reflex) $ $$ $$$ U.S. FDA 510(k) cleared: • Respiratory Flex Assay COMPETITION: FIXED A
Slide 11: Antigen vs. Molecular Point-of-Care Market
Antigen vs. Molecular Point-of-Care Market U.S Molecular Diagnostic POC: ~ $3 billions market size 100% 91% 90% 89% Antigen (%) Molecular (%) 90% 85% 82% 80% 80% 78% 75% 72% 69% 70% 65% 62% 60% 58% 55% 52% 50% 48% 45% 42% 40% 38% 35% 31% 30% 28% 24% 21% 20% 17% 14% 10% 10% 5% 2% 3% 0% 2016 2017 2018
Slide 12: Point-of-Care Molecular Diagnostics: LIAISON NES
Point-of-Care Molecular Diagnostics: LIAISON NES® Light, portable and • Emergency Departments seamlessly • Urgent Care Centers • Specialty Wards (Maternity) connected Hospital / Lab • Rural / Remote Clinics • Physicians within Network 11.5 cm, 4.5 in 3 kgs, 6.6 lbs • Physicians Groups Cloud system P
Slide 13: Transformation: 2019 to 2027
transformation: 2019 to 2027 in 2019 2021 in 2027 Revenues ~ 700 €/mln Revenues ~ 1.5 €/bn(*) Exposure to the Chinese acquisition Increased presence in the market U.S. market IVD industry IVD industry B2B Life Science Molecular Diagnostics Licensed ~10% Technologies ~15% Molecular Diagnostics Immuno
Slide 14: 2024-2027 Guidance
2024-2027 Guidance* EBITDA margin EBITDA margin EBITDA margin ~ 33% ~ 33% 36% / 37% Complete High Single Digit to deleverage Low Double Digit increase by 2027 (CAGR) Ex Covid: ~ +7% Covid: ~30 €/mln 1,148 €/mln Covid Base Business 2023 2024 2027 *Source: Diasorin 2023 Investor Day. Data @CER 2023. I
Slide 15: Sustainable long-term growth and value creation
Sustainable long-term growth and value creation DIVERSIFIED PORTFOLIO U.S. FOCUS RECURRING VS NON- RECURRING BUSINESS 15% 15% 10% 20% 50% 65% 35% 90% Licensed Technologies Rest of the World Recurring Molecular Diagnostics Europe Immunodiagnostics Non Recurring North America 15 presentation at 43rd A
Slide 16: Diasorin S.p.A. www.diasorin.com
Diasorin S.p.A. www.diasorin.com
Diasorin — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix